secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001493152-26-003606
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Oncotelic Therapeutics grants CEO up to 26,512 Series A preferred shares based on capital structure milestones
--------------------------------------------------------------------------------

- CEO Dr. Vuong Trieu receives 4,426 preferred shares (convertible to 4.426M common) for first milestone: converting $2.175M 2023 PPM Notes into 2025 Units.
- Remaining 22,086 preferred shares vest upon three milestones: $350K debt from Mast Hill Fund with $45M market cap, conversion of $3.3M Autotelic loans, and repayment of $2.175M notes.
- Each preferred share converts into 1,000 common shares; total potential dilution up to 26.512M common shares (approx. 4.99% of outstanding).
- Agreement includes accelerated vesting upon termination without cause or change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315226003606/0001493152-26-003606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315226003606/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-003606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer